Dengue and Chikungunya Symptoms

The following answer is an LLM fallback response (no citable retrieval evidence was found). --- ## Dengue Fever vs. Chikungunya Fever: Clinical Symptom Profiles Both dengue and chikungunya are mosquito-borne arboviral infections (primarily *Aedes aegypti* and *Aedes albopictus*) that share overlapping early clinical presentations, making differentiation challenging, particularly in the first 48–72 hours. However, their symptom trajectories, pathophysiological mechanisms, and complications diverge significantly. ### Dengue Fever (ICD-11: 1D20–1D22) Dengue is caused by four distinct serotypes (DENV-1 to DENV-4) of the flavivirus family. The clinical course is classically triphasic: | Phase | Timing | Key Features | |-------|--------|--------------| | **Febrile (acute)** | Days 1–7 | Abrupt high fever (39–40 °C), severe headache, retro-orbital pain, myalgia, arthralgia, nausea, vomiting, maculopapular rash, mild mucocutaneous bleeding (petechiae, positive tourniquet test) | | **Critical (plasma leakage)** | Around defervescence (days 3–7) | Temperature drops to ≤37.5 °C; increased vascular permeability → plasma leakage, hemoconcentration, thrombocytopenia, leukopenia, elevated transaminases; risk of shock (dengue shock syndrome) | | **Recovery** | Days 7–10 | Reabsorption of extravasated fluid; hemodynamic stabilization; possible reflex bradycardia and generalized pruritus | **Warning signs** (indicating progression to severe dengue) include: - Persistent vomiting - Intense abdominal pain or tenderness - Clinical fluid accumulation (ascites, pleural effusion) - Mucosal bleeding - Hepatomegaly (>2 cm) - Lethargy, restlessness, or irritability - Postural hypotension - Rising hematocrit with concurrent drop in platelet count **Severe dengue** is defined by severe plasma leakage with respiratory distress and/or shock, severe bleeding, or severe organ involvement (e.g., transaminases >1000 IU/L, myocarditis, altered mental status). **Key distinguishing features**: Retro-orbital pain, hemorrhagic manifestations, and the critical plasma-leakage phase are characteristic. Thrombocytopenia and hemoconcentration are hallmark laboratory findings. --- ### Chikungunya Fever (ICD-11: 1D40) Chikungunya is caused by the chikungunya virus (CHIKV), an alphavirus. The clinical course is biphasic (acute and chronic): | Phase | Timing | Key Features | |-------|--------|--------------| | **Acute** | Days 1–14 | Sudden high fever, **severe symmetric polyarthralgia** (often incapacitating, affecting peripheral joints), myalgia, headache, fatigue, maculopapular rash | | **Chronic** | >3 months (up to years) | Persistent arthralgia, fatigue, myalgia, sleep disorders, skin lesions, depression, reduced mobility | **Acute phase specifics**: - The classic triad is **fever, arthralgia, and rash** - Joint pain is typically **bilateral, symmetric, and severe**, often involving hands, wrists, ankles, and knees; it is disproportionately severe relative to objective joint findings - Rash is usually maculopapular, appearing 2–5 days after fever onset - Approximately 75% of infected individuals are symptomatic; ~17% may require hospitalization **Neurological complications** (rare but severe, more common in infants and elderly, typically 1–3 weeks post-infection): - Encephalitis, meningoencephalitis - Acute disseminated encephalomyelitis (ADEM) - Guillain–Barré syndrome - Optic neuropathy, neuroretinitis **Chronic phase specifics**: - Approximately 43% of affected individuals progress to a chronic phase - **Arthralgia is the dominant chronic manifestation** (present in ~27.5% of the pooled cohort sample across observational studies) - Other chronic symptoms include fatigue (8.4%), myalgia (3.2%), sleep disorders (2.2%), skin lesions (2.1%), depression (1.2%), and digestive disorders (0.9%) - Chronic rheumatologic manifestations (polyarthralgia, polyarthritis, tenosynovitis) may persist for months to years **Key distinguishing features**: The severity and persistence of joint pain, the absence of a plasma-leakage critical phase, and the high rate of chronic rheumatologic sequelae. --- ### Comparative Symptom Table | Feature | Dengue | Chikungunya | |---------|--------|-------------| | **Fever** | High (39–40 °C), biphasic course | High, acute onset | | **Arthralgia** | Mild to moderate, generalized | **Severe, symmetric, peripheral, often incapacitating** | | **Retro-orbital pain** | Common | Uncommon | | **Rash** | Maculopapular, may appear late | Maculopapular, appears early (2–5 days) | | **Hemorrhagic manifestations** | Common (petechiae, mucosal bleeding) | Rare | | **Plasma leakage / shock** | **Hallmark of severe disease** | Absent | | **Thrombocytopenia** | Prominent | Mild or absent | | **Chronic sequelae** | Uncommon | **Frequent (arthralgia, fatigue, depression)** | | **Neurological complications** | Rare (encephalopathy) | Rare but documented (encephalitis, GBS, ADEM) | | **Case fatality** | Low (<1% with proper management) | Very low | --- ### Diagnostic Considerations - **Dengue**: NS1 antigen detection (days 1–5), IgM seroconversion (day 5 onward), RT-PCR (acute phase). Serial hematocrit and platelet monitoring is essential. - **Chikungunya**: RT-PCR (acute phase, first week), IgM/IgG serology (after day 5). Cross-reactivity with other alphaviruses is possible. --- ### Management Principles - **Dengue**: Symptomatic and supportive. Avoid NSAIDs (aspirin, ibuprofen) due to bleeding risk. Oral rehydration with ORS or fruit juices; hospitalization for warning signs; judicious intravenous fluid therapy in the critical phase. - **Chikungunya**: Symptomatic. Analgesics, antipyretics, and anti-inflammatory agents (paracetamol, NSAIDs) are the mainstay. No specific antiviral therapy exists. Chronic-phase management focuses on rheumatologic rehabilitation. --- ### Critical Gaps - The retrieved evidence base does not provide head-to-head prospective comparative studies of dengue versus chikungunya symptom profiles in the same cohort. - The chronic-phase prevalence data for chikungunya derive from observational cohorts with variable follow-up durations and definitions, contributing to wide prevalence ranges (arthralgia prevalence reported from <15% to nearly 90% across studies). - Co-infection with both viruses is possible in endemic regions and may complicate the clinical picture. --- ### Conclusion Dengue is characterized by a triphasic course with a plasma-leakage critical phase, hemorrhagic manifestations, and thrombocytopenia, whereas chikungunya is defined by severe acute polyarthralgia with a high propensity for chronic rheumatologic sequelae; differentiation hinges on the presence of retro-orbital pain and bleeding (dengue) versus incapacitating symmetric joint pain and chronic arthritis (chikungunya). --- *This response is an AI-generated fallback based on general medical knowledge without citable retrieved evidence. It is intended for clinical reference only; verify against current guidelines and apply individual patient judgment.*